Provided by Tiger Trade Technology Pte. Ltd.

PolyPid Ltd.

5.19
-0.1800-3.35%
Post-market: 5.13-0.0600-1.16%19:30 EDT
Volume:168.31K
Turnover:885.85K
Market Cap:105.42M
PE:-3.52
High:5.55
Open:5.49
Low:5.06
Close:5.37
52wk High:5.73
52wk Low:3.06
Shares:20.31M
Float Shares:12.51M
Volume Ratio:2.38
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4762
EPS(LYR):-2.0900
ROE:-243.59%
ROA:-74.63%
PB:19.57
PE(LYR):-2.48

Loading ...

PolyPid’s D-PLEX₁₀₀ Application Validated by EMA, Advancing Dual EU–U.S. Reviews

TIPRANKS
·
Oct 01

EMA Validates PolyPid D-Plex100 Marketing Authorization Application, Triggers Formal Review

Reuters
·
Oct 01

European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-Plex₁₀₀

THOMSON REUTERS
·
Oct 01

PolyPid - Co and Advanz Pharma Terminate Exclusive European Agreement for D-Plex₁₀₀

THOMSON REUTERS
·
Oct 01

PolyPid Announces Participation in Upcoming Fall Investor Conferences

GlobeNewswire
·
Sep 15

Analysts Are Bullish on These Healthcare Stocks: PolyPid (PYPD), Equillium (EQ)

TIPRANKS
·
Aug 14

PolyPid Earnings Call: Priority Review, Big Azurity Deal

TIPRANKS
·
Aug 13

PolyPid Posts Wider H1 2026 Loss as Assets and Equity Decline

TIPRANKS
·
Aug 13

Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO), Liquidia Technologies (LQDA) and PolyPid (PYPD)

TIPRANKS
·
Aug 13

PolyPid Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

PolyPid Q2 FY26 Net Loss Narrows 22% to $7.8 Million

Reuters
·
Aug 12

PolyPid Q2 EPS $(0.35) Beats $(0.38) Estimate

Benzinga Earnings
·
Aug 12

Press Release: PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 12

PolyPid Ltd Expected to Post a Loss of 38 Cents a Share - Earnings Preview

Reuters
·
Aug 10

PolyPid to Report Q2 2026 Results, Host Conference Call

Reuters
·
Jul 30

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

GlobeNewswire
·
Jul 30

PolyPid NDA acceptance ‘meets or exceeds’ expectations, says Roth Capital

TIPRANKS
·
Jul 29

PolyPid Wins FDA Priority Review for D-PLEX100 NDA, Accelerating Path to Market

TIPRANKS
·
Jul 29

PolyPid Says FDA Accepts D-plex100 NDA, Grants Priority Review

Reuters
·
Jul 29

PolyPid - FDA Sets Pdufa Target Action Date of November 28, 2026 for D-Plex100

THOMSON REUTERS
·
Jul 29